title: Effect of butylscopolamine on image quality in MRI of the prostate.
abstract: OBJECTIVE
  To evaluate the impact of butylscopolamine on the quality of magnetic resonance imaging (MRI) images of the prostate.
  
  
  METHODS
  Eighty-two MRI examinations of the prostate were retrospectively analysed. MRI was performed with a combined endorectal/body phased-array coil including proton density-weighted (PD) sequence, T1-weighted turbo spin-echo (TSE)-sequence, and T2-weighted TSE-sequences. Forty milligrams of butylscopolamine was administered intramuscularly in 31 patients (im-group) and intravenously in 30 patients (iv-group). Twenty-one patients did not receive premedication with butylscopolamine (ø-group). Overall image quality, delineation of the bowel wall, and visualization of the prostate, neurovascular bundle, and pelvic lymph nodes were evaluated qualitatively using a five-point scale (from 1=excellent to 5=non-diagnostic/structure not discernible). Motion artefacts within the endorectal coil were quantified by baseline adjusted signal intensities inside the endorectal coil area.
  
  
  RESULTS
  Delineation of the bowel wall using the PD-sequence was significantly improved after both intramuscular and intravenous butylscopolamine administration (ø-group: 3.6+/-0.7; im-group: 2.9+/-0.7; iv-group: 2.9+/-0.7; p=0.001). However, there were no significant differences in motion artefacts measured within the endorectal coil (ø-group: 1.18+/-0.14; im-group: 1.15+/-0.11; iv-group: 1.12+/-0.06; p=0.39). There were also no significant differences in qualitative assessment of visualization of the prostate, neurovascular bundle, pelvic lymph nodes, and of overall image quality between the study groups.
  
  
  CONCLUSIONS
  : In conclusion, butylscopolamine had only a small effect on image quality and is not mandatory for MRI of the prostate.
authors.affiliation: Department of Radiology, Charité - Universitätsmedizin Berlin, Germany. moritz.wagner@charite.de
authors.forename: M
authors.initials: M
authors.lastname: Wagner
authors.forename: M
authors.initials: M
authors.lastname: Rief
authors.forename: J
authors.initials: J
authors.lastname: Busch
authors.forename: C
authors.initials: C
authors.lastname: Scheurig
authors.forename: M
authors.initials: M
authors.lastname: Taupitz
authors.forename: B
authors.initials: B
authors.lastname: Hamm
authors.forename: T
authors.initials: T
authors.lastname: Franiel
mesh_terms: D000368:Aged; D016477:Artifacts; D002086:Butylscopolammonium Bromide / Q000494:pharmacology*; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007090:Image Interpretation, Computer-Assisted; D007273:Injections, Intramuscular; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000494:pharmacology*; D011467:Prostate / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000473:pathology*; D012189:Retrospective Studies
chemical_list: D018727:Muscarinic Antagonists; D002086:Butylscopolammonium Bromide